期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Ailogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 years of age
1
作者 吴小津 《外科研究与新技术》 2011年第4期297-297,共1页
Objective To investigate the efficiency and safety of allogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 years of age. Methods From May 2002 to January 2010,35... Objective To investigate the efficiency and safety of allogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 years of age. Methods From May 2002 to January 2010,35 patients P 】 50 years with malignant hematological diseases received allogeneic hematopoietic 展开更多
关键词 CELL Ailogeneic hematopoietic cell transplantation for malignant hematological diseases in patients older than 50 years of age THAN
下载PDF
SVEAT score outperforms HEART score in patients admitted to a chest pain observation unit
2
作者 Daniel Antwi-Amoabeng Chanwit Roongsritong +8 位作者 Moutaz Taha Bryce David Beutler Munadel Awad Ahmed Hanfy Jasmine Ghuman Nicholas T Manasewitsch Sahajpreet Singh Claire Quang Nageshwara Gullapalli 《World Journal of Cardiology》 2022年第8期454-461,共8页
BACKGROUND Timely and accurate identification of subgroup at risk for major adverse cardiovascular events among patients presenting with acute chest pain remains a challenge.Currently available risk stratification sco... BACKGROUND Timely and accurate identification of subgroup at risk for major adverse cardiovascular events among patients presenting with acute chest pain remains a challenge.Currently available risk stratification scores are suboptimal.Recently,a new scoring system called the Symptoms,history of Vascular disease,Electrocardiography,Age,and Troponin(SVEAT)score has been shown to outperform the History,Electrocardiography,Age,Risk factors and Troponin(HEART)score,one of the most used risk scores in the United States.AIM To assess the potential usefulness of the SVEAT score as a risk stratification tool by comparing its performance to HEART score in chest pain patients with low suspicion for acute coronary syndrome and admitted for overnight observation.METHODS We retrospectively reviewed medical records of 330 consecutive patients admitted to our clinical decision unit for acute chest pain between January 1st to April 17th,2019.To avoid potential biases,investigators assigned to calculate the SVEAT,and HEART scores were blinded to the results of 30-d combined endpoint of death,acute myocardial infarction or confirmed coronary artery disease requiring revascularization or medical therapy[30-d major adverse cardiovascular event(MACE)].An area under receiving-operator characteristic curve(AUC)for each score was then calculated.C-statistic and logistic model were used to compare RESULTS A 30-d MACE was observed in 11 patients(3.33%of the subjects).The AUC of SVEAT score(0.8876,95%CI:0.82-0.96)was significantly higher than the AUC of HEART score(0.7962,95%CI:0.71-0.88),P=0.03.Using logistic model,SVEAT score with cut-off of 4 or less significantly predicts 30-d MACE(odd ratio 1.52,95%CI:1.19-1.95,P=0.001)but not the HEART score(odd ratio 1.29,95%CI:0.78-2.14,P=0.32).CONCLUSION The SVEAT score is superior to the HEART score as a risk stratification tool for acute chest pain in low to intermediate risk patients. 展开更多
关键词 Acute chest pain Risk stratification tool Symptoms history of Vascular disease Electrocardiography Age and Troponin score History Electrocardiography Age Risk factors and Troponin score
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部